Skip to main content

Table 1 Demographics, anthropometry and prevalence of atopy according to randomization group

From: Vitamin A supplementation and risk of atopy: long-term follow-up of a randomized trial of vitamin A supplementation at six and nine months of age

  VAS (n = 137) Placebo (n = 137) P value or PR (95% CI)
At enrolment    
 Age (days) 200 (183–294) n = 137 198 (183–301) n = 137 0.93
 Weight (kg) 7.1 (6.1-8.7) n = 88 7.5 (5.9-8.8) n = 79 0.35
 MUAC (mm) 144 (126–160) n = 86 144 (130–166) n = 80 0.99
 Breastfeeding 86/94 (91%) 80/90 (89%) 0.55
 DTP3 vaccinated 84/137 (61%) 95/137 (69%) 0.16
At follow up    
 Age (years) 7.4 (7.0-7.7) n = 137 7.4 (7.0-7.7) n = 137 0.72
 Weight (kg) 20.0 (17.0-24.0) n = 136 20.5 (17.0-23.5) n = 137 0.78
 Height (cm) 119 (112–126) n = 137 118 (111–125) n = 137 0.46
 MUAC (mm) 166 (150–184) n = 137 166 (152–180) n = 137 0.77
 BCG scar 105/132 (80%) 110/131 (84%) 0.35
 Pig at the house 43/134 (32%) 47/133 (35%) 0.57
Atopy in all children (n = 263) 22/131 (17%) 18/132 (14%) 1.23 (0.69-2.18)
Atopy stratified by sex    
 Boys (n = 135) 11/67 (16%) 7/68 (10%) 1.60 (0.66-3.90)
 Girls (n = 128) 11/64 (17%) 11/64 (17%) 1.00 (0.46-2.15)
  1. VAS = vitamin A supplementation; PR = prevalence ratio adjusted for age and sex; MUAC = mid-upper arm circumference; DTP3 = 3rd dose of diphtheria-tetanus-whole cell pertussis vaccine due at 14 weeks of age.